Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Condition: Colorectal Cancer Interventions: Drug: Mesalamine 2400 MG; Drug: Mesalamine 1200 MG; Other: Placebo Sponsors: Christoph Gasche; Prof. Dr. Gabriela Möslein, Germany; Prof. Dr. Hans Vasen, The Netherlands; Prof. Dr. med. Jan Lubinski, Poland; Prof. Dr. med. Yaron Niv, Israel; Univ. Prof. Dr. Judith Karner-Hanusch, Austria; Ann-Sofie Backman, MD PhD, Sweden Not yet recruiting - verified March 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asacol | Cancer | Cancer & Oncology | Colorectal Cancer | HNPCC | Lialda | Lynch Syndrome | Middle East Health